LFLisa Frigati

Lisa Frigati

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lisa Frigati has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early outcomes of South African children with persistent viral non-suppression following switch to dolutegravir-based antiretroviral therapy

    by Mila Guerrini, Minette Maré, Claire Hulsman, Leonore Greybe, Juanita Lishman, Clair Edson, Thania Hisham, Lisa Frigati, Helena Rabie

    Background: Since 2019 dolutegravir-based antiretroviral therapy (ART) has been introduced for South African children and adolescents living with HIV (CALHIV), including those with persistent viral non-suppression. Current guidelines recommend the reuse of abacavir when switching CALHIV weighing < 30 kg with persistent viral non-suppression to dolutegravir-based ART. Objectives: We aimed to describe the viral suppression rates, clinical outcomes and risk factors for non-suppression in CALHIV switching to dolutegravir-based ART following persistent viral non-suppression. Method: We performed a retrospective cohort study at Tygerberg Hospital in Cape Town, South Africa. Results: We identified 39 children, 18 girls (46.2%). Median age at switch to a dolutegravir-based regimen was 7.2 years. Median duration on treatment pre-switch was 5.6 years. After switching to a dolutegravir-based regimen, 21 children (55.3%) achieved viral suppression. Abacavir was recycled with dolutegravir in 31 children (available viral load for 30/31) of whom 50.0% suppressed. Treatment interruptions were common, with 26 (66.7%) and 15 (38.5%) children experiencing at least one interruption in care before and after switching to a dolutegravir-based regimen, respectively. Conclusion: We provide evidence that recycling abacavir is safe in children with persistent viral non-suppression switching to dolutegravir. Supporting adherence and preventing therapy interruption is key to success.

  • Open Access

    SAHCS Guideline for the prevention, diagnosis and management of cryptococcal disease among persons living with HIV: Update to induction treatment for cryptococcal meningitis

    by Nelesh P. Govender, Graeme Meintjes, Jonathan Falconer, Kyla Murphy, Jeremy Nel, Helena Rabie, Lisa Frigati, Denasha L. Reddy, Halima Dawood, Ebrahim Variava, et al.

    The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.

  • Open Access

    Co‐Occurrence of Pulmonary Tuberculosis and Hydatid Disease in a Single Patient: Highlighting the Dual Burden in Resource‐Limited Settings

    by Noelle van der Walt, Pierre Goussard, Lisa Frigati, Shyam Venkatakrishna, Savvas Andronikou, Andre Gie A, Carmen Jacobs, Jacques Janson, Pawel Schubert


  • Open Access

    Opportunities to Optimize Outcomes of Diagnosis and Treatment of HIV and Syphilis in Pregnancy: the Quest to Eliminate Maternal and Vertical Transmission

    by Dvora Joseph Davey, Alex de Voux, Natalie Shaetonhodi, Michael Marks, Lisa Frigati, Tendesayi Kufa

    Background: There is an urgent need to improve interventions for HIV and syphilis in pregnancy to achieve elimination. Results: The tenets of vertical transmission strategies for HIV and syphilis overlap but have varying success due to differences in their transmission dynamics, diagnoses, and treatment. Key principles include prevention of maternal infection, screening and diagnosis early and throughout antenatal care, curative treatment (syphilis), viral load suppression (HIV), early infant diagnosis and treatment (HIV and congenital syphilis). We recommend improved guidelines, provider training and focused research and surveillance, including implementation studies to align HIV and syphilis screening and treatment during pregnancy. Opportunities to integrate syphilis screening and treatment into antenatal and HIV care enable providers to offer comprehensive maternal care. Conclusion: Integrated HIV/syphilis services ensure a cohesive and person-centered approach, improving health outcomes through streamlined, efficient, and family-centered care pathways. We recommend key interventions to reduce HIV and syphilis in pregnancy and prevent vertical transmission.


  • New developments in antiretroviral therapy strategies to improve clinical management of neonates and young infants with HIV

    by Lisa Jane Frigati, Shaun Barnabas, Adrie Bekker

    Purpose of review: Clinical and virological outcomes in early-treated cohorts of children living with HIV have been sub-optimal. This is in part due to the demands on the caregiver of adhering to twice a day antiretroviral treatment (ART) for their newborn infants. Administering ART to neonates can be challenging and frequently requires separate drugs in liquid formulations and multiple dose adjustments. We reviewed literature from 01 January 2015 to 31 December 2024 on infant outcomes, antiretroviral drugs, updated dosing recommendations, new formulations and potential strategies to enhance adherence when ART is started in the neonatal and young infant period. Recent findings: There are now pharmacokinetic (PK) data to inform the use of abacavir and lamivudine in liquid and solid formulations in the neonatal period and to support the use of lamivudine and nevirapine in preterm infants. A dosing strategy for dolutegravir in the first month of life has been informed by recent studies. Summary: Studies are ongoing with regards to dolutegravir in various formulations. Long-acting antiretroviral therapy and broadly neutralizing antibodies are currently being studied in neonates and young infants. Addressing maternal clinical and psychosocial health and is a key factor in ensuring infants achieve viral suppression and decreased morbidity.


  • Open Access

    Mother‐child dyads living with HIV in the Western Cape, South Africa: Undetectable = Undetectable?

    by Kim Anderson, Helena Rabie, Brian S. Eley, Lisa Frigati, James Nuttall, Emma Kalk, Alexa Heekes, Gayathri Sridhar, Leigh Ragone, Vani Vannappagari, et al.

    Introduction: Globally, children living with HIV continue to lag behind UNAIDS targets for viral suppression (VS). Because studies with linked mother‐child data are limited, we describe VS and associated factors among young children in a setting with early infant HIV testing (at birth, age 10 weeks and 6 months) and early protease inhibitor‐based first‐line antiretroviral therapy (ART). Methods: We analysed routinely collected mother‐child data for children living with HIV born 2018–2022 in Western Cape province, South Africa (followed through mid‐2023). We assessed associations between child and maternal viral load (VL) results at 12 and 24 months after child ART start using logistic regression, adjusted for child sex, birthyear, severity of child immunodeficiency at ART start, maternal age and timing of maternal HIV diagnosis. Results: Among 2219 children living with HIV; 30% were diagnosed at birth (≤7 days), 41% before age 1 year (8−365 days) and 29% at age >1 year. Overall, 5% ( n = 112/2219) of children died, a third of whom had not started ART; 90% of children ( n = 1990) started ART, at median age 5 months (IQR 1–16). Median follow‐up from ART start was 26 months (IQR 14–40). Among children with available VL at 12 months ( n = 853/1582), 24 months ( n = 614/1129) and 36 months ( n = 350/658) after ART start, 36%, 43% and 48% were virally suppressed, respectively (VLp <0.001). Conclusions: Less than half of children on ART achieved VS, and children were more likely to achieve VS if their mothers were also virally suppressed. Significant efforts are needed to support mother‐child dyads to achieve optimal VS.


  • Airway Management Strategies for Diphtheria‐Induced Severe Upper Airway Obstruction and Pneumonia in Children: Challenges and Solutions in a Low‐Middle Income Settings

    by Renisha Desai, Noor Parker, Marc Merven, Lisa Frigati, Shaegan Irusen, Francois Retief, Shyam Venkatakrishna, Savvas Andronikou, Pierre Goussard


  • Open Access

    Association of prior tuberculosis with cardiovascular status in perinatally HIV-1-infected adolescents

    by Itai M Magodoro, Carlos Eduardo Guerrero-Chalela, Emma Carkeek, Nana Akua Asafu-Agyei, Nomawethu Jele, Lisa J Frigati, Landon Myer, Jennifer Jao, Mpiko Ntsekhe, Katalin A Wilkinson, et al.

    Background: Whether, and how, co-occurring HIV-1 infection (HIV) and tuberculosis (TB) impact cardiovascular status, especially in adolescents with perinatally acquired HIV (APHIV), have not been examined. We hypothesised that APHIV with previous TB disease have worse cardiac efficiency than APHIV without TB, which is mediated by increased inflammation and disordered cardiometabolism. Methods: APHIV in Cape Town, South Africa, completed 3T cardiovascular magnetic resonance examination and high sensitivity C reactive protein (hsCRP), fasting plasma glucose (FPG), low-density lipoprotein (LDL) and triglyceride measurement. Ventriculoarterial coupling (VAC) was estimated as the ratio of arterial elastance (Ea) to ventricular end-systolic elastance (Ees). Regression models were applied to estimate cross-sectional associations between Ea/Ees ratio and TB status, with decomposition of these associations into direct and mediated effects of hsCRP, FPG and dyslipidaemia, if any, attempted. Results: We enrolled 43 APHIV with prior TB and 23 without TB of mean (SD) age 15.0 (1.5) and 15.4 (1.7) years, respectively. Prior TB was associated with lower Ea/Ees ratio (0.59 (0.56 to 0.64)) than no TB (0.66 (0.62 to 0.70)), which corresponded to an adjusted mean difference −0.06 (−0.12 to 0.01) (p=0.048). However, previous TB was not associated with increased hsCRP, FPG, LDL or triglycerides nor were hsCRP, FPG, LDL and triglycerides associated with Ea/Ees ruling out their mediated effects in the association between TB and cardiac efficiency. Conclusions: Previous TB in APHIV is associated with comparatively reduced cardiac efficiency, related to altered VAC. The clinical significance of these findings requires further study, including a wider range of biomarkers of specific immune pathways.

  • Open Access

    Severe Mycoplasma pneumoniae infection in a young child: An emerging increase in incidence?

    by P Goussard, H Rabie, L Frigati, A Gie, S Irusen, C Jacobs, S Venkatakrishna, S Andronikou


  • Open Access

    Respiratory infections in low and middle-income countries

    by Lisa Frigati, Leonore Greybe, Savvas Andronikou, Ernst Eber, Shyam Sunder B. Venkatakrishna, Pierre Goussard